TNGX earnings analysis
What we found in TNGX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q text does not include the income statement, balance sheet, cash flow statement, segment disclosures, or MD&A, so current-quarter revenue, margins, EPS, liquidity, and cash-burn trends cannot be quantified from the filing content provided. Management reported effective disclosure controls as of June 30, 2026 and no material changes to the risk factors from the 2025 Form 10-K. The filing provided no quantitative forward guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure Controls Remain Effective
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026.
- No Material Litigation Identified
- The company reported no material litigation proceedings that management believes are probable to adversely affect the business, and stated that it is not currently party to such proceedings.
- Insider Trading Plan Disclosed
- The filing disclosed a Rule 10b5-1 arrangement for up to 210,000 shares to be sold by the President of Research and Development, with a stated duration through October 31, 2027.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Core Risk Profile Unchanged
- The company stated that there have been no material changes to the risk factors in its 2025 Form 10-K filed March 5, 2026; therefore, the filing provides no evidence of reduced exposure to previously disclosed risks.
- Additional Insider Selling Plan
- A Rule 10b5-1 plan permits the Principal Accounting Officer to sell up to 68,655 shares through June 15, 2027, which could create potential share-supply and investor-perception pressure.
- Potential Litigation Costs
- The company disclosed that litigation can generate defense and settlement costs and divert management resources, even though it reported no currently material proceedings.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the extracted 10-Q text.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Tango Therapeutics, Inc. reported a significant increase in operating losses for Q1 2026, losing $45.5 million, an increase from $39.9 million in Q1 2025. The company continued to face substantial cash burn, but remains…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TNGX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever